Inotek Pharmaceuticals Presentations at ARVO 2009

April 29, 2009

Inotek Pharmaceuticals announced that preclinical data supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875, will be presented in a poster session at ARVO.

INO-8875 is a highly selective adenosine-1 receptor agonist currently completing a Phase 1/2 trial as a topical agent for the treatment of elevated intraocular pressure (IOP) associated with primary open angle glaucoma and ocular hypertension. The preclinical data suggests that INO-8875 lowers IOP primarily by restoring trabecular meshwork outflow, the most important outflow pathway to maintain IOP in healthy eyes. Additionally, INO-8875 may have a secondary mechanism of action to decrease IOP by reducing aqueous humor production.

Read the full release.




Jump down to form below to submit your own comments

Comments are closed.